{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-024426","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.335551+00:00","generated_at":"2026-06-01T03:20:31.440083+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"First two patients treated in pilot study of NB1 bone graft device for spine fusion","bullets":["Two patients treated in Australia in multicenter pilot study evaluating NB1 (NELL-1+DBM) for TLIF in degenerative disc disease.","Study targets 30 adult subjects; design reviewed by FDA Division of Orthopedic Devices to support US pivotal trial.","Preclinical studies showed strong safety profile and fusion success; CEO cites $3 billion global spine fusion market opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-024426","json":"https://secwatch.observer/filing/0001493152-24-024426.json","markdown":"https://secwatch.observer/filing/0001493152-24-024426.md","text":"https://secwatch.observer/filing/0001493152-24-024426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315224024426/0001493152-24-024426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315224024426/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:20:31.440083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}